Table 5 Multivariable Analysis of adverse growth outcomes and clinical adverse events in Infants Exposed to HIV relative to Infants Not Exposed to HIV adjusted for breastfeeding duration < 6 months
Infant Growth and Clinical Outcomes | Unadjusted OR (95%CI) | P Value | Adjusted OR (95%CI) | P Value |
|---|---|---|---|---|
Underweight at 3 or 6 months | ||||
 Infants exposed to HIV | 0.55 (1.84–1.66) | 0.292 | 0.44 (0.11–1.79) | 0.254 |
 Infants not exposed to HIV | Ref |  | Ref |  |
Stunting at 3 or 6 months | ||||
 Infants exposed to HIV | 0.15 (0.07–0.30) | < 0.001 | 0.15 (0.07–0.34) | < 0.001 |
 Infants not exposed to HIV | Ref |  | Ref |  |
Wasting at 3 or 6 months | ||||
 Infants exposed to HIV | 2.65 (1.10–6.36) | 0.030 | 2.86 (1.09–7.50) | 0.033 |
 Infants not exposed to HIV | Ref |  | Ref |  |
Rash/Skin Disease | ||||
 Infants Exposed to HIV | 5.42 (3.03–9.69) | < 0.001 | 7.06 (3.69–13.51) | < 0.001 |
 Infants not exposed to HIV | Ref |  | Ref |  |
Upper Respiratory Tract Infection | ||||
 Infants Exposed to HIV | 3.52 (1.88–6.57) | < 0.001 | 3.01 (1.50–6.03) | 0.002 |
 Infants not exposed to HIV | Ref |  | Ref |  |
Any Clinical Adverse Event | ||||
 HIV Exposed Uninfected | 6.35 (3.78–10.68) | < 0.001 | 8.89 (4.75–16.61) | < 0.001 |
 Breastfeeding< 6 months | Ref |  | Ref |  |